Program
cemdisiran
Also written as “Cemdisiran”, “Pozelimab + Cemdisiran” and “ALN-CC5”.
Its studies are mostly in Hemoglobinuria, Paroxysmal · Geographic Atrophy · Myasthenia Gravis · Glomerulonephritis, IGA · Atypical Hemolytic Uremic Syndrome, led by 2 companies.
Drug pageCemdisiran: every studyAll 12 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Regeneron Pharmaceuticalsits history only | 74 open or running | phase 3since Sep 27, 2021 | Oct 21, 2020 | Jul 31, 2028phase 3 · NCT06541704 |
| Alnylam Pharmaceuticals | 30 open or running | phase 2since Jan 23, 2015 | Jan 23, 2015 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Alnylam Pharmaceuticals only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jan 23, 2015First study: phase 2 study in Hemoglobinuria, ParoxysmalFirst studyNCT02352493 · 62 enrolled · Spain, United Kingdom
- Dec 9, 2015Named cemdisiranINNProposed as its International Nonproprietary Name in WHO's List 114
- Sep 25, 2017Phase 2 study in Atypical Hemolytic Uremic SyndromeNCT03303313 · Bosnia and Herzegovina, Canada, Estonia and more
- Feb 13, 2019Phase 2 study in Glomerulonephritis, IGANCT03841448 · 31 enrolled · Canada, France, Malaysia and more
TargetBeta
“A proprietary formulation composed of small-interfering RNAs (siRNAs) directed against terminal complement component 5 (C5) of the complement pathway ”NCIt, by rule
Other programs on C5
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| eculizumabrule | AstraZeneca | phase 4 | 38 |
| ravulizumabrule | AstraZeneca | phase 4 | 35 |
| pozelimabrule | Regeneron Pharmaceuticals | phase 4 | 14 |
| zilucoplanrule | UCB | phase 3 | 14 |
| vilobelimabrule | inflarx-gmbh | phase 3 | 13 |
| Crovalimabrule | Hoffmann-La Roche | phase 3 | 10 |
| ABBV-6628 | AbbVie | phase 2 | 1 |
Studies
All 3 Alnylam Pharmaceuticals leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03841448Glomerulonephritis, IGA · Canada, France, Malaysia and more | 2 | Terminated | Mar 17, 2022 | 31 |
| NCT03303313Atypical Hemolytic Uremic Syndrome · Bosnia and Herzegovina, Canada, Estonia and more | 2 | Withdrawn | Sep 12, 2018 | 0 |
| NCT02352493Hemoglobinuria, Paroxysmal · Spain, United Kingdom | 2 | Completed | Apr 2016 | 62 |
How it is read
Names in the registry
- “Cemdisiran”, 9 entries
- “Pozelimab + Cemdisiran”, 1 entry
- “ALN-CC5”, 1 entry
Conditions, from the studies’ own filings
- Hemoglobinuria, Paroxysmal, 5 studies
- Geographic Atrophy, 1 study
- Myasthenia Gravis, 1 study
- Glomerulonephritis, IGA, 1 study
- Atypical Hemolytic Uremic Syndrome, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.